China-based gene therapy developer Lingyi Biotechnology Co., Ltd has reportedly raised close to RMB 100 million (USD 14.5 million) in a Series A finance round. This significant investment was co-led by Efung Capital and Huafang Asset Management, with additional participation from Transfar Science City, Sequoia China, and Huaiji Capital. The funds raised will be allocated towards the construction of the company’s headquarters in Hangzhou, as well as the development of its gene therapy pipeline and technology platform.
Lingyi Biotechnology’s Commitment to Advancing Gene Therapy
Founded in 2021, Lingyi Biotechnology has established itself as a key player in the gene therapy space with a single gene genetic disease animal model functional verification platform. The company’s product pipeline is diverse, covering diseases related to metabolism, the central nervous system (CNS), and ophthalmology, among others. This financing round serves as a testament to the company’s potential to contribute meaningfully to the advancement of gene therapy treatments.
Investor Confidence and Lingyi’s Future Prospects
The confidence shown by investors such as Efung Capital and Huafang Asset Management, along with Transfar Science City, Sequo China, and Huaiji Capital, underscores the promising future of Lingyi Biotechnology. With the capital raised, Lingyi is well-positioned to bolster its research and development efforts, potentially leading to breakthroughs in the treatment of genetic diseases.-Fineline Info & Tech
